12 Mar
2020

2020: A Busy Year for CRISPR Patents at the EPO

The much-watched validity dispute over the Broad Institute’s patent for fundamental CRISPR-Cas9 technology – recently revoked by the EPO Board of Appeal – is not the only CRISPR-related IP issue to watch out for in Europe this year, explains HGF’s Dr Emma Longland.

The EPO Board of Appeal’s recent revocation of the CRISPR-Cas9 patent, EP2771468 – belonging to the Broad Institute, Harvard College and the Massachusetts Institute of Technology – has garnered a great deal of attention since January. However, IP professionals interested in keeping up to speed with the technology’s patent landscape should also pay attention to several other important CRISPR applications going through the EPO opposition and appeals process this year.

The Broad Institute and its collaborators were among the innovators working on CRISPR gene editing during its early development in 2012 and 2013. Thanks to a strategy of accelerating the prosecution of their related patent applications at the EPO, they were the first to get granted foundational CRISPR patents in Europe.  And several patents other than EP2771468 are now at various stages of the opposition and appeal process.

Importantly, these include EP2825654, which does not suffer from the fatal priority error that led to the revocation of EP2771468 by the Boards of Appeal. The opposition oral proceedings for this patent have been set for later this year, and the preliminary view of the opposition division is that the claimed subject-matter is not inventive, so there will be keen interest in what conclusion the opposition division reaches at the end of the oral proceedings. 

Commonly viewed as the group on the other side of the CRISPR IP war from the Broad, the University of California, the University of Vienna, and Emmanuelle Charpentier also have three foundational CRISPR patents granted. These are up before the opposition division in 2020: 

  • Opposition oral proceedings for the first patent, EP2800811 were held at the beginning of February, and the patent was maintained following only minimal amendments. 
  • Opposition oral proceedings for the second patent, EP3241902, have just been scheduled for October this year; this patent is directed at the use of CRISPR-Cas systems as a DNA-targeting tool, for targeting heterologous protein activity to areas of DNA. The preliminary opinion of the opposition division that was issued with the summons to oral proceedings is generally in favour of the patentees, as it was for the parent case, EP2800811
  • The opposition deadline for the third patent, EP3401400, was at the very beginning of the year, and four oppositions were filed.

Of course, not only these two groups of patentees will come in front of the EPO.  Other parties also have CRISPR gene editing patents that claim effective dates in 2012 and 2013, and we can expect considerable activity for these cases this year as well: 

  • Patent EP2828386 was granted last year to Vilnius University, so that it has an opposition deadline in April this year; although only directed at in vitro methods of modifying DNA, this patent pre-dates even the University of California et al. patents.
  • ToolGen Incorporated’s patent EP2912175 was opposed by six parties last year, and ToolGen will need to file their response to those oppositions shortly.
  • Harvard University’s Patent EP2931891 was opposed by four parties earlier this month. 
  • The early Merck CRISPR patents, in the name of Sigma-Aldrich at the EPO, are also going to see significant post-grant activity this year;  EP2928496, EP3360964, and EP3363902 all have opposition deadlines falling over the summer, and EP3138910 has opposition oral proceedings scheduled for June.  Opposition proceedings were initiated for EP3138911 and EP3138912 in September last year, so we can expect the patentee’s responses to be in the second half of this year.

Therefore, the EPO is going to see considerable post-grant activity this year on the early CRISPR gene-editing patents.  Many will be watching this activity with interest, to try to get an indication as to who will eventually own key patent rights to this important technology.

Unfortunately, though, it will be many years before there is any certainty on this, not least because patentees can be expected to use their pending applications to keep their options open and most, if not all, patents will be dragged in front of the Boards of Appeal before any final decision is reached.

Dr Emma Longland

Patent Director | HGF

London